Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

NCT02273518 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Asasantin ER, new formulation I
DRUG: Asasantin ER, new formulation II
DRUG: Asasantin ER, present commercial formulation

Sponsor

Boehringer Ingelheim